Paris and New York, 04 June 2018
Quantum Genomics (Euronext Growth: ALQGC, OTCQX: QNNTF), a biopharmaceutical company developing a new class of drugs directly acting on the brain to treat unmet medical needs in the field of cardiovascular diseases, announces the approval of its generic name firibastat for its QGC001 molecule.
The World Health Organisation approved the International Non-proprietary Name (INN or generic name) firibastat for the active ingredient developed by Quantum Genomics, until now known by the code name RB150 or QGC001. This name, recognised worldwide, is designed to be used without ambiguity by all health care professionals. This generic name is especially important for identifying, prescribing and dispensing drugs safely.
“It is a usual step in drug development but it remains an important symbol and a mark of recognition of the innovative nature of our product,” emphasises Fabrice Balavoine, Research & Development Director.
Firibastat is currently in phase IIb of clinical trials in the field of high blood pressure. The candidate medicine targets the Renin Angiotensin System, directly in the brain, and, through a triple mechanism of action, enables it to work, for the first time in mono-therapy, simultaneously on the vessels, the heart and the kidney. Firibastat thus offers promising perspectives in the treatment of high blood pressure and also in heart failure, for which a IIb phase will be launched in the last quarter of 2018, and for which the design will be released on June 26.
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs based on the Brain Aminopeptidase A Inhibition (BAPAI). The only company in the world exploring this innovative approach, which directly targets the brain, it relies on its 20 years of academic and clinical research in some of the largest French laboratories (The French National Institute of Health and Medical Research (INSERM), the Scientific Centre for National Research (CNRS), the Collège de France, and the Paris-Descartes University). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with heart failure dies within five years).
Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).
|Jean-Philippe Milon |
+33 (0)1 85 34 77 70 | email@example.com
|Marc Karako |
+33 (0)1 85 34 77 70 | firstname.lastname@example.org
|Samuel Beaupain |
Media Relations and Scientific Communications
+33 (0)6 88 48 48 02 | email@example.com
|Nathalie Boumendil |
+33 (0)6 85 82 41 95 | firstname.lastname@example.org
|Edison Advisors (U.S.)|
|Tirth Patel |
+1 (646) 653-7035 | email@example.com